Adverse Effects of Androgen Deprivation Therapy on Persistent Genitourinary Complications After Carbon Ion Radiotherapy for Prostate Cancer
Purpose To determine the risk factors for persistent late genitourinary (GU) morbidity after carbon ion radiotherapy (C-ion RT) for prostate cancer. Methods and Materials Between April 2000 and November 2003, a Phase II study of 175 prostate cancer patients was performed to assess C-ion RT with a do...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2008-09, Vol.72 (1), p.78-84 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 84 |
|---|---|
| container_issue | 1 |
| container_start_page | 78 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 72 |
| creator | Ishikawa, Hitoshi, M.D., Ph.D Tsuji, Hiroshi, M.D., Ph.D Kamada, Tadashi, M.D., Ph.D Hirasawa, Naoki, M.D Yanagi, Takeshi, M.D., Ph.D Mizoe, Jun-Estu, M.D., Ph.D Akakura, Koichiro, M.D., Ph.D Suzuki, Hiroyoshi, M.D., Ph.D Shimazaki, Jun, M.D., Ph.D Nakano, Takashi, M.D., Ph.D Tsujii, Hirohiko, M.D., Ph.D |
| description | Purpose To determine the risk factors for persistent late genitourinary (GU) morbidity after carbon ion radiotherapy (C-ion RT) for prostate cancer. Methods and Materials Between April 2000 and November 2003, a Phase II study of 175 prostate cancer patients was performed to assess C-ion RT with a dose fractionation (66 Gray equivalent in 20 fractions) established from previous Phase I-II studies. The effects of the clinical and dosimetric parameters on the occurrence of persistent GU toxicity in 172 patients who survived for >18 months after C-ion RT were examined retrospectively. C-ion RT alone was performed for 33 low-risk patients, and 139 high-risk patients received C-ion RT combined with androgen deprivation therapy (ADT). Results Grade 1 and 2 persistent GU toxicities developed in 36 (21%) and 3 (2%) patients, respectively. The use of long-course ADT (≥24 months) and acute GU toxicity were associated with the occurrence of persistent toxicity by multivariate analysis ( p = 0.016 and p = 0.048, respectively), but short-course ADT ( |
| doi_str_mv | 10.1016/j.ijrobp.2007.12.044 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_21124426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301608000382</els_id><sourcerecordid>S0360301608000382</sourcerecordid><originalsourceid>FETCH-LOGICAL-c553t-74f3a0d5f2058def4400eebb94e1339cdb376ce4ff9c7e34d8ce64be5d5d91573</originalsourceid><addsrcrecordid>eNqFks-KFDEQxoMo7rj6BiIBz90mnfS_izCM67qw4KIreAvdScVNO5M0SXZgnsGXttoeELx4CMnh-1Wqvq8Iec1ZyRlv3k2lm2IY57JirC15VTIpn5AN79q-EHX9_SnZMNGwQqD4grxIaWKMcd7K5-SCd7JuJO835NfWHCEmoFfWgs6JBku33sTwAzz9AHN0xyG74On9A8RhPlF83iHgUgaf6TV4l8NjdH6IJ7oLh3nv9B8g0a3NEOluiCMyN3i-DMaFfK5jQ6R3MaQ8ZECR1xBfkmd22Cd4db4vybePV_e7T8Xt5-ub3fa20HUtctFKKwZmaluxujNgpWQMYBx7CVyIXptRtI0GaW2vWxDSdBoaOUJtatPzuhWX5O1aF393KmmXQT_o4D0aoCrOKymrBlVyVWnsMkWwCs044JiKM7UkoCa1JqCWBBSvFCaA2JsVmx_HA5i_0NlyFLxfBYAjHh3EpQPA-Y2LSwMmuP_98G8BvXcebd__hBOkCePwaJ_iKiGgvi5bsCwB63ABRFeJ384zsTk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adverse Effects of Androgen Deprivation Therapy on Persistent Genitourinary Complications After Carbon Ion Radiotherapy for Prostate Cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Ishikawa, Hitoshi, M.D., Ph.D ; Tsuji, Hiroshi, M.D., Ph.D ; Kamada, Tadashi, M.D., Ph.D ; Hirasawa, Naoki, M.D ; Yanagi, Takeshi, M.D., Ph.D ; Mizoe, Jun-Estu, M.D., Ph.D ; Akakura, Koichiro, M.D., Ph.D ; Suzuki, Hiroyoshi, M.D., Ph.D ; Shimazaki, Jun, M.D., Ph.D ; Nakano, Takashi, M.D., Ph.D ; Tsujii, Hirohiko, M.D., Ph.D</creator><creatorcontrib>Ishikawa, Hitoshi, M.D., Ph.D ; Tsuji, Hiroshi, M.D., Ph.D ; Kamada, Tadashi, M.D., Ph.D ; Hirasawa, Naoki, M.D ; Yanagi, Takeshi, M.D., Ph.D ; Mizoe, Jun-Estu, M.D., Ph.D ; Akakura, Koichiro, M.D., Ph.D ; Suzuki, Hiroyoshi, M.D., Ph.D ; Shimazaki, Jun, M.D., Ph.D ; Nakano, Takashi, M.D., Ph.D ; Tsujii, Hirohiko, M.D., Ph.D</creatorcontrib><description>Purpose To determine the risk factors for persistent late genitourinary (GU) morbidity after carbon ion radiotherapy (C-ion RT) for prostate cancer. Methods and Materials Between April 2000 and November 2003, a Phase II study of 175 prostate cancer patients was performed to assess C-ion RT with a dose fractionation (66 Gray equivalent in 20 fractions) established from previous Phase I-II studies. The effects of the clinical and dosimetric parameters on the occurrence of persistent GU toxicity in 172 patients who survived for >18 months after C-ion RT were examined retrospectively. C-ion RT alone was performed for 33 low-risk patients, and 139 high-risk patients received C-ion RT combined with androgen deprivation therapy (ADT). Results Grade 1 and 2 persistent GU toxicities developed in 36 (21%) and 3 (2%) patients, respectively. The use of long-course ADT (≥24 months) and acute GU toxicity were associated with the occurrence of persistent toxicity by multivariate analysis ( p = 0.016 and p = 0.048, respectively), but short-course ADT (<24 months) had no effect on the development of toxicity ( p = 0.35). The 5-year actuarial complication rate of 80 patients undergoing long-course ADT was 31.1%; the corresponding rate for the 92 patients who received no ADT or short-course ADT was 22.2%. Conclusion Adverse effects with long-course ADT on persistent GU morbidity were observed in this study. Additional investigation is needed to identify suitable ADT administration according to risk groups, but long-course ADT should not be adopted for non–high-risk prostate cancer patients to reduce the GU toxicity rate with C-ion RT.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2007.12.044</identifier><identifier>PMID: 18456419</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Analysis of Variance ; Androgen Antagonists - adverse effects ; Androgen Antagonists - therapeutic use ; ANDROGENS ; Carbon ion therapy ; CARBON IONS ; Carbon Radioisotopes - adverse effects ; Carbon Radioisotopes - therapeutic use ; CARCINOMAS ; Combined Modality Therapy - methods ; DISEASE INCIDENCE ; Dose Fractionation ; Dose–volume histogram ; FRACTIONATED IRRADIATION ; Hematology, Oncology and Palliative Medicine ; Hormonal therapy ; Humans ; Incidence ; Male ; Middle Aged ; Orchiectomy ; PATIENTS ; PROSTATE ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - radiotherapy ; Prostatic Neoplasms - surgery ; Radiation Injuries - epidemiology ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Retrospective Studies ; Risk Factors ; TOXICITY ; Urethra - anatomy & histology ; Urethra - radiation effects ; Urinary complications ; Urination Disorders - epidemiology ; Urination Disorders - etiology ; Urogenital System - radiation effects</subject><ispartof>International journal of radiation oncology, biology, physics, 2008-09, Vol.72 (1), p.78-84</ispartof><rights>Elsevier Inc.</rights><rights>2008 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c553t-74f3a0d5f2058def4400eebb94e1339cdb376ce4ff9c7e34d8ce64be5d5d91573</citedby><cites>FETCH-LOGICAL-c553t-74f3a0d5f2058def4400eebb94e1339cdb376ce4ff9c7e34d8ce64be5d5d91573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2007.12.044$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18456419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/21124426$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishikawa, Hitoshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Tsuji, Hiroshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Kamada, Tadashi, M.D., Ph.D</creatorcontrib><creatorcontrib>Hirasawa, Naoki, M.D</creatorcontrib><creatorcontrib>Yanagi, Takeshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Mizoe, Jun-Estu, M.D., Ph.D</creatorcontrib><creatorcontrib>Akakura, Koichiro, M.D., Ph.D</creatorcontrib><creatorcontrib>Suzuki, Hiroyoshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Shimazaki, Jun, M.D., Ph.D</creatorcontrib><creatorcontrib>Nakano, Takashi, M.D., Ph.D</creatorcontrib><creatorcontrib>Tsujii, Hirohiko, M.D., Ph.D</creatorcontrib><title>Adverse Effects of Androgen Deprivation Therapy on Persistent Genitourinary Complications After Carbon Ion Radiotherapy for Prostate Cancer</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose To determine the risk factors for persistent late genitourinary (GU) morbidity after carbon ion radiotherapy (C-ion RT) for prostate cancer. Methods and Materials Between April 2000 and November 2003, a Phase II study of 175 prostate cancer patients was performed to assess C-ion RT with a dose fractionation (66 Gray equivalent in 20 fractions) established from previous Phase I-II studies. The effects of the clinical and dosimetric parameters on the occurrence of persistent GU toxicity in 172 patients who survived for >18 months after C-ion RT were examined retrospectively. C-ion RT alone was performed for 33 low-risk patients, and 139 high-risk patients received C-ion RT combined with androgen deprivation therapy (ADT). Results Grade 1 and 2 persistent GU toxicities developed in 36 (21%) and 3 (2%) patients, respectively. The use of long-course ADT (≥24 months) and acute GU toxicity were associated with the occurrence of persistent toxicity by multivariate analysis ( p = 0.016 and p = 0.048, respectively), but short-course ADT (<24 months) had no effect on the development of toxicity ( p = 0.35). The 5-year actuarial complication rate of 80 patients undergoing long-course ADT was 31.1%; the corresponding rate for the 92 patients who received no ADT or short-course ADT was 22.2%. Conclusion Adverse effects with long-course ADT on persistent GU morbidity were observed in this study. Additional investigation is needed to identify suitable ADT administration according to risk groups, but long-course ADT should not be adopted for non–high-risk prostate cancer patients to reduce the GU toxicity rate with C-ion RT.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis of Variance</subject><subject>Androgen Antagonists - adverse effects</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>ANDROGENS</subject><subject>Carbon ion therapy</subject><subject>CARBON IONS</subject><subject>Carbon Radioisotopes - adverse effects</subject><subject>Carbon Radioisotopes - therapeutic use</subject><subject>CARCINOMAS</subject><subject>Combined Modality Therapy - methods</subject><subject>DISEASE INCIDENCE</subject><subject>Dose Fractionation</subject><subject>Dose–volume histogram</subject><subject>FRACTIONATED IRRADIATION</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hormonal therapy</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Orchiectomy</subject><subject>PATIENTS</subject><subject>PROSTATE</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Radiation Injuries - epidemiology</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>TOXICITY</subject><subject>Urethra - anatomy & histology</subject><subject>Urethra - radiation effects</subject><subject>Urinary complications</subject><subject>Urination Disorders - epidemiology</subject><subject>Urination Disorders - etiology</subject><subject>Urogenital System - radiation effects</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks-KFDEQxoMo7rj6BiIBz90mnfS_izCM67qw4KIreAvdScVNO5M0SXZgnsGXttoeELx4CMnh-1Wqvq8Iec1ZyRlv3k2lm2IY57JirC15VTIpn5AN79q-EHX9_SnZMNGwQqD4grxIaWKMcd7K5-SCd7JuJO835NfWHCEmoFfWgs6JBku33sTwAzz9AHN0xyG74On9A8RhPlF83iHgUgaf6TV4l8NjdH6IJ7oLh3nv9B8g0a3NEOluiCMyN3i-DMaFfK5jQ6R3MaQ8ZECR1xBfkmd22Cd4db4vybePV_e7T8Xt5-ub3fa20HUtctFKKwZmaluxujNgpWQMYBx7CVyIXptRtI0GaW2vWxDSdBoaOUJtatPzuhWX5O1aF393KmmXQT_o4D0aoCrOKymrBlVyVWnsMkWwCs044JiKM7UkoCa1JqCWBBSvFCaA2JsVmx_HA5i_0NlyFLxfBYAjHh3EpQPA-Y2LSwMmuP_98G8BvXcebd__hBOkCePwaJ_iKiGgvi5bsCwB63ABRFeJ384zsTk</recordid><startdate>20080901</startdate><enddate>20080901</enddate><creator>Ishikawa, Hitoshi, M.D., Ph.D</creator><creator>Tsuji, Hiroshi, M.D., Ph.D</creator><creator>Kamada, Tadashi, M.D., Ph.D</creator><creator>Hirasawa, Naoki, M.D</creator><creator>Yanagi, Takeshi, M.D., Ph.D</creator><creator>Mizoe, Jun-Estu, M.D., Ph.D</creator><creator>Akakura, Koichiro, M.D., Ph.D</creator><creator>Suzuki, Hiroyoshi, M.D., Ph.D</creator><creator>Shimazaki, Jun, M.D., Ph.D</creator><creator>Nakano, Takashi, M.D., Ph.D</creator><creator>Tsujii, Hirohiko, M.D., Ph.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>OTOTI</scope></search><sort><creationdate>20080901</creationdate><title>Adverse Effects of Androgen Deprivation Therapy on Persistent Genitourinary Complications After Carbon Ion Radiotherapy for Prostate Cancer</title><author>Ishikawa, Hitoshi, M.D., Ph.D ; Tsuji, Hiroshi, M.D., Ph.D ; Kamada, Tadashi, M.D., Ph.D ; Hirasawa, Naoki, M.D ; Yanagi, Takeshi, M.D., Ph.D ; Mizoe, Jun-Estu, M.D., Ph.D ; Akakura, Koichiro, M.D., Ph.D ; Suzuki, Hiroyoshi, M.D., Ph.D ; Shimazaki, Jun, M.D., Ph.D ; Nakano, Takashi, M.D., Ph.D ; Tsujii, Hirohiko, M.D., Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c553t-74f3a0d5f2058def4400eebb94e1339cdb376ce4ff9c7e34d8ce64be5d5d91573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis of Variance</topic><topic>Androgen Antagonists - adverse effects</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>ANDROGENS</topic><topic>Carbon ion therapy</topic><topic>CARBON IONS</topic><topic>Carbon Radioisotopes - adverse effects</topic><topic>Carbon Radioisotopes - therapeutic use</topic><topic>CARCINOMAS</topic><topic>Combined Modality Therapy - methods</topic><topic>DISEASE INCIDENCE</topic><topic>Dose Fractionation</topic><topic>Dose–volume histogram</topic><topic>FRACTIONATED IRRADIATION</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hormonal therapy</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Orchiectomy</topic><topic>PATIENTS</topic><topic>PROSTATE</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Radiation Injuries - epidemiology</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>TOXICITY</topic><topic>Urethra - anatomy & histology</topic><topic>Urethra - radiation effects</topic><topic>Urinary complications</topic><topic>Urination Disorders - epidemiology</topic><topic>Urination Disorders - etiology</topic><topic>Urogenital System - radiation effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishikawa, Hitoshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Tsuji, Hiroshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Kamada, Tadashi, M.D., Ph.D</creatorcontrib><creatorcontrib>Hirasawa, Naoki, M.D</creatorcontrib><creatorcontrib>Yanagi, Takeshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Mizoe, Jun-Estu, M.D., Ph.D</creatorcontrib><creatorcontrib>Akakura, Koichiro, M.D., Ph.D</creatorcontrib><creatorcontrib>Suzuki, Hiroyoshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Shimazaki, Jun, M.D., Ph.D</creatorcontrib><creatorcontrib>Nakano, Takashi, M.D., Ph.D</creatorcontrib><creatorcontrib>Tsujii, Hirohiko, M.D., Ph.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishikawa, Hitoshi, M.D., Ph.D</au><au>Tsuji, Hiroshi, M.D., Ph.D</au><au>Kamada, Tadashi, M.D., Ph.D</au><au>Hirasawa, Naoki, M.D</au><au>Yanagi, Takeshi, M.D., Ph.D</au><au>Mizoe, Jun-Estu, M.D., Ph.D</au><au>Akakura, Koichiro, M.D., Ph.D</au><au>Suzuki, Hiroyoshi, M.D., Ph.D</au><au>Shimazaki, Jun, M.D., Ph.D</au><au>Nakano, Takashi, M.D., Ph.D</au><au>Tsujii, Hirohiko, M.D., Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse Effects of Androgen Deprivation Therapy on Persistent Genitourinary Complications After Carbon Ion Radiotherapy for Prostate Cancer</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2008-09-01</date><risdate>2008</risdate><volume>72</volume><issue>1</issue><spage>78</spage><epage>84</epage><pages>78-84</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose To determine the risk factors for persistent late genitourinary (GU) morbidity after carbon ion radiotherapy (C-ion RT) for prostate cancer. Methods and Materials Between April 2000 and November 2003, a Phase II study of 175 prostate cancer patients was performed to assess C-ion RT with a dose fractionation (66 Gray equivalent in 20 fractions) established from previous Phase I-II studies. The effects of the clinical and dosimetric parameters on the occurrence of persistent GU toxicity in 172 patients who survived for >18 months after C-ion RT were examined retrospectively. C-ion RT alone was performed for 33 low-risk patients, and 139 high-risk patients received C-ion RT combined with androgen deprivation therapy (ADT). Results Grade 1 and 2 persistent GU toxicities developed in 36 (21%) and 3 (2%) patients, respectively. The use of long-course ADT (≥24 months) and acute GU toxicity were associated with the occurrence of persistent toxicity by multivariate analysis ( p = 0.016 and p = 0.048, respectively), but short-course ADT (<24 months) had no effect on the development of toxicity ( p = 0.35). The 5-year actuarial complication rate of 80 patients undergoing long-course ADT was 31.1%; the corresponding rate for the 92 patients who received no ADT or short-course ADT was 22.2%. Conclusion Adverse effects with long-course ADT on persistent GU morbidity were observed in this study. Additional investigation is needed to identify suitable ADT administration according to risk groups, but long-course ADT should not be adopted for non–high-risk prostate cancer patients to reduce the GU toxicity rate with C-ion RT.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18456419</pmid><doi>10.1016/j.ijrobp.2007.12.044</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2008-09, Vol.72 (1), p.78-84 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_21124426 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Aged Aged, 80 and over Analysis of Variance Androgen Antagonists - adverse effects Androgen Antagonists - therapeutic use ANDROGENS Carbon ion therapy CARBON IONS Carbon Radioisotopes - adverse effects Carbon Radioisotopes - therapeutic use CARCINOMAS Combined Modality Therapy - methods DISEASE INCIDENCE Dose Fractionation Dose–volume histogram FRACTIONATED IRRADIATION Hematology, Oncology and Palliative Medicine Hormonal therapy Humans Incidence Male Middle Aged Orchiectomy PATIENTS PROSTATE Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - radiotherapy Prostatic Neoplasms - surgery Radiation Injuries - epidemiology Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Retrospective Studies Risk Factors TOXICITY Urethra - anatomy & histology Urethra - radiation effects Urinary complications Urination Disorders - epidemiology Urination Disorders - etiology Urogenital System - radiation effects |
| title | Adverse Effects of Androgen Deprivation Therapy on Persistent Genitourinary Complications After Carbon Ion Radiotherapy for Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T17%3A33%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20Effects%20of%20Androgen%20Deprivation%20Therapy%20on%20Persistent%20Genitourinary%20Complications%20After%20Carbon%20Ion%20Radiotherapy%20for%20Prostate%20Cancer&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Ishikawa,%20Hitoshi,%20M.D.,%20Ph.D&rft.date=2008-09-01&rft.volume=72&rft.issue=1&rft.spage=78&rft.epage=84&rft.pages=78-84&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2007.12.044&rft_dat=%3Celsevier_osti_%3ES0360301608000382%3C/elsevier_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18456419&rft_els_id=S0360301608000382&rfr_iscdi=true |